Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients (FORUM)

AstraZeneca

Status: Terminated

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00241462

D6997-NL-001

FORUM

Details and patient eligibility

About

The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.

Enrollment: 150 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal
• Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
• Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment

Exclusion criteria

• Life threatening metastases